|
By Brian Wilson-Lead Contributor
|
|
Sunday, 08 December 2013 23:43 |
 After Q1 2013 (link) we entertained the thought of seeing Dendreon Corporation (NASDAQ: DNDN) at $2/share before 2016, which led to some backlash.
|
|
Read more...
|
|
By Brian Wilson-Lead Contributor
|
|
Wednesday, 04 December 2013 22:59 |
 In our previous article (link) on Unilife (NASDAQ: UNIS), published on November 27th 2013, we predicted that UNIS would probably break 100% in YTD gains.
|
|
Read more...
|
|
By Brian Wilson - Lead Contributor
|
|
Wednesday, 04 December 2013 13:33 |
 We are revisiting the vaccine and drug developer Soligenix ahead of 9 events that will occur in 2014 – all of which are important to the company and its investors.
|
|
Read more...
|
|
By Mary Davila
|
|
Sunday, 01 December 2013 22:56 |
|
After some new and aggressive developments, we are once again taking a look at Sorrento Therapeutics (NASDAQ: SRNE).
|
|
Read more...
|
|
By Brian Wilson - Lead Contributor
|
|
Wednesday, 27 November 2013 10:57 |
|
Unilife Corp (NASDAQ: UNIS), a company with a decently large pipeline of customizable injection devices, saw another big rally this year after the company announced – on November 20th 2013 (link) – that the company signed a long-term supply agreement with the London-based generic pharmaceutical company Hikma Pharmaceuticals (LSE:HIK).
|
|
Read more...
|
|
By Brian Wilson - Lead Contributor
|
|
Monday, 25 November 2013 10:45 |
|
Investors who follow Aegerion Pharmaceuticals (NASDAQ: AEGR) may have noticed that it has been tested by the bears a few times in recent weeks.
|
|
Read more...
|
|
By Brian Wilson-Lead Contributor
|
|
Friday, 22 November 2013 01:26 |
|
It hasn't been a good year for short sellers betting against the rapidly growing healthcare conglomerate OPKO Health (NYSE: OPK) and its CEO/Chairman - Dr. Phillip Frost.
|
|
Read more...
|
|
By Brian Wilson - Lead Contributor
|
|
Thursday, 21 November 2013 15:05 |
|
Ampio Pharmaceuticals (NASDAQ: AMPE) is a late stage pharmaceutical company that has been focusing on the clinical development of Ampion and Optina – two drugs that target very large indications. At time of writing, the company is trading at a $327 M valuation, with about $32 M in cash as of September 30th 2013.
|
|
Read more...
|
|
By Brian Wilson-Lead Contributor
|
|
Wednesday, 20 November 2013 08:57 |
|
Yesterday’s trading was overwhelmingly bullish for the controlled release and targeted drug developer Intellipharmaceutics (NASDAQ: IPCI) after the FDA gave final approval to the company’s dexmethylphenidate hydrochloride extended-release capsules at the 15 and 30 mg doses on Monday night.
|
|
Read more...
|
|
By Brian Wilson-Lead Contributor
|
|
Sunday, 17 November 2013 23:22 |
|
As a close follower of the hematologic cancer developers, I wanted to point out the following important data releases that are scheduled for the upcoming 55th annual American Society of Hematology Meeting – to be held December 7-10, 2013 in New Orleans.
|
|
Read more...
|
|
|
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>
|
|
Page 17 of 56 |
